New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione

Clinical Therapeutics

Volumn 25, Issue 7, 2003, Pages 1895-1917

  Braunstein, Seth ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diabetes mellitus; Insulin resistance; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CONFUSION; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DRUG FATALITY; DRUG MECHANISM; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRRITABILITY; LACTIC ACIDOSIS; LIVER TOXICITY; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; POLYPHARMACY; REVIEW; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

EID: 0043204379     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80195-9     Document Type: Article

References (106)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
3. American Diabetes Association. National Diabetes Fact Sheet. Available at: http://www.diabetes.org/main/info/facts/facts_natl.jsp. Accessed June 16, 2003.
4. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
5. Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association. Diabetes Care. 1998;21:310-314.
6. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318-368.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
9. Feld S. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management - 2002 update. Endocr Pract. 2002;8(Suppl 1):40-82.
10. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(Suppl 1):S33-S49.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
12. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
14. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
15. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(Suppl 3):C10-C13.
16. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
17. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311-320.
18. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 1992;41:1076-1083.
19. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA. 2000;283:221-228.
20. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610.
21. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA. 2001;285:1585-1591.
22. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
23. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
24. Rubins HB, Robins SJ. Conclusions from the VA-HIT study. Am J Cardiol. 2000;86:543-544.
25. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
26. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 2002;287:360-372.
27. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
28. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
29. Jones NP, Mather R, Owen S, et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia. 2000;43(Suppl 1):A192. Abstract.
30. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-288.
31. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
32. Actos [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals America, Inc; 2002.
33. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.
34. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797-802.
35. Miyazaki Y, Mahankali A, Matsuda, M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
36. Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57:921-930; discussion 931-932.
37. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review. Clin Ther. 2000;22:1151-1168.
38. Scheen AJ. Hepatotoxicity with thiazolidinediones: Is it a class effect? Drug Saf. 2001;24:873-888.
39. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815-821.
40. Salzman A, Patel I. Rosiglitazone is not associated with hepatotoxicity. Diabetes. 1999;48(Suppl 1):A95. Abstract.
41. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
42. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am. 2001;30:909-933.
43. Lebovitz HE. Insulin secretagogues: Old and new. Diabetes Rev. 1999;7:139-153.
44. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
45. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
46. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265-266. Letter.
47. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
48. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
49. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021-1029.
50. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
51. Ovalle F, Bell DSH. Thiazolidinedione induced recovery of pancreatic beta cell function. Diabetes. 2000;49(Suppl 1):A120. Abstract.
52. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA. 2000;283:1695-1702.
53. Fonseca V, Biswas N, Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A100. Abstract.
54. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
55. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
56. Triplitt CL, Cersosimo E, Miyazaki Y, et al. Mechanisms of improved glucose metab-olism with combination metformin and rosiglitazone therapy Presented at the 38th Annual Meeting of the European Association for the Study of Diabetes; September 1-5, 2002; Budapest, Hungary. Abstract.
57. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40-47.
58. Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:737-745.
59. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Diabetes. 2001;50(Suppl 2):A106. Abstract.
60. Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care. 2002;25:1251-1252.
61. Wyne KL, Drexler AJ, Miller JL, et al. Constructing an algorithm for managing type 2 diabetes: Focus on role of the thiazolidinediones. Postgrad Med. 2003;Spec No:63-72.
62. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232.
63. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabet Med. 2002;19:572-574.
64. Fontbonne AM, Eschwège EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care. 1991;14:461-469.
65. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
66. Pyörälä M, Miettinen H, Halonen E et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000;20:538-544.
67. Salomaa V, Riley W, Kark JD, et al. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation. 1995;91:1432-1443.
68. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
69. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993;92:141-146.
70. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
71. Murphy KJ, Salzman A. Rosiglitazone is superior to glybunde in establishing long-term glycemic control in patients with type 2 diabetes. Presented at: 82nd Annual Meeting of the American Endocrine Society; June 21-24, 2000; Toronto, Ontario, Canada.
72. Avena R, Mitchell ME, Nylen ES, et al. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg. 1998;28:1024-1032.
73. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): Evidence of a potent anti-inflammatory effect. Diabetes. 2001;50(Suppl 2):A68. Abstract.
74. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058-2064.
75. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1998;12:181-186.
76. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(Suppl 1):A267. Abstract.
77. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
78. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
79. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid artenal wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
80. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
81. Murakami T, Mizuno S, Ohsato K, et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol. 1999;84:92-94.
82. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study Diabetes. 2001;50:2384-2389.
83. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
84. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): A cohort study. Lancet. 1999;353:1649-1652.
85. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-466.
86. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
87. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
88. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
89. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med. 1995;99:420-426.
90. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
91. Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab. 2000;85:1563-1568.
92. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation. 1998;98:2513-2519.
93. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
94. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
95. Gotto AM. Lipid management in diabetic patients: Lessons from prevention trials. Am J Med. 2002;112(Suppl 8A):19S-26S.
96. Freed MI, Miller AK, Inglis AM, et al. Rosiglitazone, a PPAR-gamma agonist, does not alter the pharmacokinetics of nifedipine, a cytochrome P450 3A4-substrate. Diabetes. 1998;57(Suppl 1):A94. Abstract.
97. Fuell D, Zhou J, Freed MI. Effects of rosiglitazone to improve glycemic control in type 2 diabetes patients taking beta-blockers. Poster presented at: 83rd Annual Meeting of the Endocrine Society; June 20-23, 2001; Denver, Colorado.
98. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
99. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet. 2000;355:253-259.
100. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
101. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010.
102. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
103. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: Data from the GISSI-3 study. Circulation. 1997;96:4239-4245.
104. Dandona P, Mohanty P, Aljada A, et al. Evidence of a potent anti-inflammatory effect of rosiglitazone in mononuclear cells. Poster presented at: 37th Annual Meeting of the European Association for the Study of Diabetes; September 9-13, 2001; Glasgow, United Kingdom. Abstract.
105. Weston WM, Heise MA, Porter LE, et al. Rosiglitazone-mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients. Diabetes. 2001;50(Suppl 2):A134-A135. Abstract.
106. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev. 2002;18(Suppl 3):S82-S85.